Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Clinical trial NCT00431561 · COMPLETED

Trial details

NCT number: NCT00431561
Sponsor: Isarna Therapeutics GmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma Anaplastic Astrocytoma

Start date: 2003-04-01
Primary completion: 2009-03-01
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.